Qilu Hospital of Shandong University, Jinan, China
Lingliya Tang , Kun Song , Ran Chu , Zhongshao Chen , Yong Zhao , Shuaixin Wang
Background: Epithelial ovarian cancer (EOC) has been extensively studied. However, no prediction model has been carried out on the prognosis of elderly patients. Our study aims to explore survival patterns in elderly EOC patients. Methods: Data were extracted from the Surveillance, Epidemiology, and End Results (SEER) database. Patients over 65 with EOC between 2004 and 2014 were included for model training and validation, while 2015 for external validation. COX proportional-hazards regression model was used to identify risk factors and applied them to the prediction model. We then evaluated performance of our model through receiver operating characteristic (ROC) curve, calibration curve and decision curve analysis (DCA). Risk stratification system was used to reflect the survival. To facilitate daily use, we developed an online application. Results: A total of 6141 patients were included. COX regression models indicated 10 independent risk factors. Our model was proved to have good performance with AUC of ROC curve: 0.768(95CI:0.749-0.788), 0.748 (95CI:0.733-0.763), 0.766 (95CI:0.750-0.781) for 1-, 3-, 5-year OS in the training cohort and 0.776 (95CI:0.757-0.796), 0.760 (95CI:0.745-0.775), 0.784 (95CI:0.769-0.799) for CSS. In the validation cohort, 0.800 (95CI:0.773-0.827), 0.770 (95CI:0.748-0.793), 0.787 (95CI:0.765-0.810) for OS and 0.808 (95CI:0.780-0.836), 0.780 (95CI:0.758-0.803), 0.801 (95CI:0.779-0.824) for CSS. In the risk stratification system, the low-risk group had the highest survival rate. Almost all patients in the low- and intermediate-risk groups underwent surgery, about 1/3 patients in the high-risk group did not receive surgery. Their survival rates were not optimistic, and patients over 85 were more likely to be classified as high-risk. Conclusions: A predictive model was constructed to evaluate survival for elderly EOC patients and demonstrated good predictive value that we can apply to help physicians make clinical decisions and plan treatment.
The points of predictive model. | ||||||||||
---|---|---|---|---|---|---|---|---|---|---|
Age (Points) | 65-69 (0) | 70-74 (7) | 75-79 (20) | 80-84 (43) | ≥85 (56) | FIGO stage (Points) | Ⅰ (0) | Ⅱ (25) | Ⅲ (77) | Ⅳ (100) |
Race (Points) | Black (18) | White (5) | None of the above (0) | Surgery (Points) | No (48) | Yes (0) | ||||
Histological type (Points) | Serous (18) | Endometrial (0) | Clear (19) | Mucus (27) | Lymphadenectomy (Points) | No (23) | Yes (0) | |||
Grade (Points) | G1(0) | G2 (14) | G3 (21) | Undifferentiated (16) | Unknown (14) | Chemotherapy (Points) | No/Unknown (22) | Yes (0) | ||
Laterality (Points) | Unilateral (0) | Bilateral (15) | Marital status (Points) | Married (0) | Widowed (7) | Divorced (13) | Unmarried (13) | |||
Total Points (probability) | ||||||||||
1 year OS 63 (0.95) 117 (0.9) 173 (0.8) 209 (0.7) 236 (0.6) 259 (0.5) 280 (0.4) 300 (0.3) 322 (0.2) | ||||||||||
3 year OS -28 (0.95) 26 (0.9) 83 (0.8) 118 (0.7) 145 (0.6) 168 (0.5) 189 (0.4) 210 (0.3) 232 (0.2) 259 (0.1) | ||||||||||
5 year OS -14 (0.9) 42 (0.8) 77 (0.7) 104 (0.6) 127 (0.5) 148 (0.4) 169 (0.3) 191 (0.2) 218 (0.1) |
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Abstract Disclosures
2019 ASCO Annual Meeting
First Author: Lubina Arjyal
2023 ASCO Gastrointestinal Cancers Symposium
First Author: Bahar Laderian
2023 ASCO Annual Meeting
First Author: Masatoshi Kudo
2021 ASCO Annual Meeting
First Author: Malcolm Isaiah Ryan